28.02.2013 - Belgian Gimv launches a new Healthcare and Medtech fund to invest in the European health and care sectors.
The European investment company, which manages investments of 1.8bn in 85 portfolio companies, will initially invest €50m in the new fund. The Flemish Government will also contribute €50m through Gimv's reference shareholder, VPM. The fund is seeking to attract additional investments from institutional investors.
A formal first closing is planned in the coming year, said the investment company.Over the next six years, the fund aims to invest in 10 to 15 healthcare and medtech companies in the Benelux, Germany and France. The amount per investment can peak to €25m, both in equity and quasi-equity. With a term of 12 years, the fund presents itself as a long-term partner for the projects in which it will invest. The Gimv Health & Care team will be responsible for the management of the fund.
”The ageing population, a rising number of chronic diseases and better informed patients continue to push up healthcare demand and costs“ commented Urbain Vandeurzen, Chairman of the Gimv Board of Directors ”With the new fund, we want to encourage innovative companies and service providers in the sector to respond to this."
The Health & Care fund is not Gimv's first project in this field. The Flemish Government's venture capital fund for biotech companies, Biotech Fonds Vlaanderen, is managed by Gimv. Gimv is also responsible for the management of two infrastructure funds (DG Infra+ and DG Infra Yield). In early 2009, Gimv established the Gimv-XL fund for investments in larger Flemish growth companies. Later that year, the Gimv-Agri+ Investment Fund was launched in cooperation with the famers' league Boerenbond. Lastly, in 2011, the Gimv Arkiv Tech Fund II was set up as part of the second ARKimedes arrangement.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.